Evidence map›Paper›PMID 31311618›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2019

Improving preparedness to respond to cross-border hepatitis A outbreaks in the European Union/European Economic Area: towards comparable sequencing of hepatitis A virus.

Theresa Enkirch, Ettore Severi, Harry Vennema, Lelia Thornton, Jonathan Dean, Maria-Louise Borg, Anna Rita Ciccaglione, Roberto Bruni, Iva Christova, Siew Lin Ngui and 30 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. The European Union One Health 2020 Zoonoses Report.EFSA journal. European Food Safety Authority · 2021
    Article
  5. Viral hepatitis update: Progress and perspectives.World journal of gastroenterology · 2021
    Review
  6. Review
  7. High impact of molecular surveillance on hepatitis A outbreak case detection in Sweden: a retrospective study, 2009 to 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Article
  8. Lessons from intensified surveillance of viral hepatitis A, Israel, 2017 and 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Article
  9. Persisting higher prevalence of hepatitis A virus RNA in blood donors, France, 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

Theresa EnkirchPublic Health Agency of Sweden, Solna, Sweden.
Ettore SeveriEuropean Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
Harry VennemaNational Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Lelia ThorntonHSE - Health Protection Surveillance Centre, Dublin, Ireland.
Jonathan DeanNational Virus Reference Laboratory, Dublin, Ireland.
Maria-Louise BorgMinistry of Health, Msida, Malta.
Anna Rita CiccaglioneNational Institute of Health, Rome, Italy.
Roberto BruniNational Institute of Health, Rome, Italy.
Iva ChristovaNational Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
Siew Lin NguiPublic Health England (PHE), London, United Kingdom.
Koye BalogunPublic Health England (PHE), London, United Kingdom.
Vratislav NěmečekNational Institute of Public Health, Prague, Czech Republic.
Mia KontioNational Institute for Health and Welfare (THL), Helsinki, Finland.
Mária TakácsNational Public Health Institute, Budapest, Hungary.
Andrea HettmannNational Public Health Institute, Budapest, Hungary.
Rita KorotinskaCentre for Disease Prevention and Control, Riga, Latvia.
Arthur LöveLandspitali- National University Hospital, Reykjavik, Iceland.
Ana AvellónCarlos III Institute of Health, Madrid, Spain.
Milagros Muñoz-ChimenoCarlos III Institute of Health, Madrid, Spain.
Rita de SousaNational Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal.
Denisa JantaNational Institute of Public Health, Bucharest, Romania.
Jevgenia EpšteinHealth Board, Tallinn, Estonia.
Sofieke KlamerScientific Institute of Public Health, Brussels, Belgium.
Vanessa SuinSciensano, Directorate Infectious diseases in humans, Brussels, Belgium.
Stephan W AberleCenter for Virology, Medical University of Vienna, Vienna, Austria.
Heidemarie HolzmannCenter for Virology, Medical University of Vienna, Vienna, Austria.
Kassiani MellouHellenic Centre for Disease Control and Prevention, Athens, Greece.
Josefine Lundberg EderthPublic Health Agency of Sweden, Solna, Sweden.
Lena SundqvistPublic Health Agency of Sweden, Solna, Sweden.
Anne-Marie Roque-AfonsoNational Reference Centre for Hepatitis A, Villejuif, France.
Sanja Kurečić FilipovićCroatian Institute of Public Health, Zagreb, Croatia.
Mario PoljakInstitute of Microbiology and Immunology, Ljubljana, Slovenia.
Line VoldNorwegian institute of Public Health, Oslo, Norway.
Kathrine Stene-JohansenNorwegian institute of Public Health, Oslo, Norway.
Sofie MidgleyStatens Serum Institut (SSI), Copenhagen, Denmark.
Thea Kølsen FischerStatens Serum Institut (SSI), Copenhagen, Denmark.
Mirko FaberRobert Koch Institute (RKI), Berlin, Germany.
Jürgen J WenzelNational Reference Laboratory for HAV, Regensburg University Medical Center, Regensburg, Germany.
Johanna TakkinenEuropean Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
Katrin LeitmeyerEuropean Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionSequence-based typing of hepatitis A virus (HAV) is important for outbreak detection, investigation and surveillance. In 2013, sequencing was central to resolving a large European Union (EU)-wide outbreak related to frozen berries. However, as the sequenced HAV genome regions were only partly comparable between countries, results were not always conclusive.AimThe objective was to gather information on HAV surveillance and sequencing in EU/European Economic Area (EEA) countries to find ways to harmonise their procedures, for improvement of cross-border outbreak responses.MethodsIn 2014, the European Centre for Disease Prevention and Control (ECDC) conducted a survey on HAV surveillance practices in EU/EEA countries. The survey enquired whether a referral system for confirming primary diagnostics of hepatitis A existed as well as a central collection/storage of hepatitis A cases' samples for typing. Questions on HAV sequencing procedures were also asked. Based on the results, an expert consultation proposed harmonised procedures for cross-border outbreak response, in particular regarding sequencing. In 2016, a follow-up survey assessed uptake of suggested methods.ResultsOf 31 EU/EEA countries, 23 (2014) and 27 (2016) participated. Numbers of countries with central collection and storage of HAV positive samples and of those performing sequencing increased from 12 to 15 and 12 to 14 respectively in 2016, with all countries typing an overlapping fragment of 218 nt. However, variation existed in the sequenced genomic regions and their lengths.ConclusionsWhile HAV sequences in EU/EEA countries are comparable for surveillance, collaboration in sharing and comparing these can be further strengthened.

Indexed as

Disease OutbreaksEuropeEuropean UnionHepatitis AHepatitis A virusHumansMolecular TypingPopulation SurveillanceRNA, ViralSequence Analysis, DNAWhole Genome SequencingRNA, Viralcapacity buildingEuropean Unionfoodborne diseasesHAVhepatitis A virussequence analysissurveys and questionnaires

Identifiers

PMID31311618
PMCPMC6636214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.